Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach. 1st Cancer Update.

Arabian Journal of Chemistry

Volumn 6, Issue 1, 2013, Pages 35-48

  Noolvi, Malleshappa N ^a   Patel, Harun M ^a  

^a ASBASJSM College of Pharmacy   (India)

Author keywords

Anticancer activity; Fusion; QSAR; Rational design; Synthesis 3 (benzylideneamino) 7 chloro 2 phenyl quinazoline 4(3H) one

Indexed keywords

ANTI-TUMOR AGENTS; ANTICANCER ACTIVITIES; CANCER CELL LINES; QSAR; QUINAZOLINES; RATIONAL DESIGN; RING OPENING;

AMINO ACIDS; CELL CULTURE; FUSION REACTIONS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ENZYMES;

EID: 84871687627     PISSN: 18785352     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arabjc.2010.12.031     Document Type: Article

References (20)

1. Adams J. Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 2001, 101:2271.
2. Alley M.C., Scudiero D.A., Monks P.A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48:589-601.
3. Badiger A.M., Noolvi M.N., Nayak P.V. QSAR study of Benzthiazole derivatives as p56 lck inhibitors. Lett. Drug Des. Discov. 2006, 3:550-560.
4. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature 2001, 411:355.
5. Boyd M.R., Paul K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 19:91-109.
6. Cohen P. Protein kinases-the major drug targets for the twenty first century. Nat. Rev. Drug Discov. 2002, 1:309.
7. Dumas J. Growth factor receptor kinase inhibitors; recent advances in clinical impact. Curr. Opin. Drug Discov. Devel. 2001, 4:378.
8. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., O'Reilley T., Traxler P., Chaudhari B., Fretz H., Zimmermann J., Meyer T., Carvatti G., Furet P., Manley P.W. Protein kinases as targets for anti-cancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 2002, 93:79-98.
9. Fricker J. Tyrosine kinase inhibitors: The next generation. Lancet Oncol. 2006, 7:621.
10. Grever M.R., Schepartz S.A., Chabner B.A. The national cancer institute: cancer drug discovery and development program. Semin. Oncol. 1992, 19:622-638.
11. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinase: targets for the cancer therapy. Nat. Rev. Cancer 2004, 4:361.
12. Jordan J.D., Landau E.M., Iyengar R. Signaling of networks: the origin of the multicellular multi-tasking. Cell 2000, 103:193.
13. Manjula S.N., Noolvi M.N., Parihar K.V., Manohara Reddy S.A., Ramani V., Gadad A.K., Singh G., Kutty N.G., Rao M. Synthesis and anti-tumour activity of optically active thiourea and their 2-aminobenzothiazole derivatives: A novel class of anticancer agents. Eur. J. Med. Chem. 2009, 44:2923-2929.
14. Noolvi M.N., Patel H.M. 2D QSAR studies on a series of quinazoline derivatives as Tyrosine Kinase (EGFR) Inhibitor: An Approach to Design Anticancer Agents. Lett. Drug Des. Discov. 2010, 7:556-586.
15. Noolvi, M.N., Patel, H.M., Bhardwaj, V.B., 2011. An approach to design anticancer agents by 2D QSAR studies on a series of quinazoline analogues as tyrosine kinase (erbB-2) inhibitors. Med. Chem. 7, in press.
16. Peter B., Robert H.B., Craig S.H., Laurent F.A.H., Mark H., Jason G.K., Jane K., Teresa K., Donald J.O., Stuart E.P., Emma J.W., Ingrid W. Design, synthesis and in vitro antitumor activity of 4-amino quinoline and 4-amino quinazoline derivatives targeting EGFR tyrosine kinase. Bioorg. Med. Chem. Lett. 2006, 16:4908.
17. Ranson M. Epidermal growth receptor tyrosine kinase inhibitors. Br. J. Cancer 2004, 90:2250.
18. Skehan P., Storeng R., Scudiero D., Monks A., McMohan J., Vistica D., Warren J.R., Bokesch H., Kenny S., Boyd M.R. New colorimetric cytotoxicity assay for anti-cancer drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
19. Slichenmeyer W.J., Elliott W.L., Fry D.W. A pan erbB-tyrosine kinase inhibitors. Semin. Oncol. 2001, 28:67.
20. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nat. Rev. 2001, 2:127.